Company profile
TransMedics Group, Inc.
NASDAQ: TMDX · Healthcare · Medical - Devices
#197 of 1,418 Healthcare companies by revenue74th-percentile growth
EA Score
77B+FH 84DQ 71GM 70SS 70
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ listing tenure, growth stability
Methodology →Revenue TTM
$635.9M
Rev growth YoY (TTM)
+30.2%
Net income (FY)
$190.3M
Employees
898
as of 2026-08-09
Market cap
$2.9B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$605.5M$605.5M2025
Net income$190.3M$190.3M2025
Operating income$108.6M$108.6M2025
Total assets$1.1B$1.1B2025
Liabilities$595.3M$595.3M2025
Equity$473.1M$473.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product62%
Service Revenue38%
By geography
Not disclosed.
The read
What is TransMedics Group, Inc.’s revenue?
TransMedics Group, Inc. booked $605.5M in FY2025 revenue, growing 37% year over year — faster than most Healthcare companies we track, at a 31.4% net margin.
Peers · Healthcare
TG Therapeutics, Inc.72BOPKO Health, Inc.74BInsmed Incorporated66BUFP Technologies, Inc.80B+Veradigm Inc.——Azenta, Inc.75B+Neighbors
Essex →Key facts
CEOWaleed H. Hassanein
SectorHealthcare
IndustryMedical - Devices
HeadquartersAndover, MA
ExchangeNASDAQ: TMDX
Employees898
IPO date2019-05-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.